Jin Hyoung Kang

Central Nervous System Activity of Lazertinib in EGFR ‐Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‐LU20‐15 and LU21‐01

Dong Hyun Kim, Min Hee Hong, Hyun Ae Jung, Tae Min Kim et autres

BACKGROUND: Central nervous system (CNS) involvement remains a major cause of mortality in patients with epidermal growth factor receptor (EGFR)-mutated nonsmall cell lung cancer (NSCLC), particularly, after progression on EGFR tyrosine kinase inhibitors (TKIs). This pooled analysis evaluated the efficacy of lazertinib …

kr, us, jp (code pays fourni par la source)

Perioperative Durvalumab for Resectable Non–Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial

John Victor Heymach, Jie He, David Harpole, Tetsuya Mitsudomi et autres

In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival (EFS) and pathologic complete response in patients with resectable non–small cell lung cancer (R-NSCLC), with a safety profile consistent with the individual agents. We report EFS from …

us, cn, jp, kr, mx, es, it, ca, pl, gb, at, ru, ar, hu, vn, tw, in, de (code pays fourni par la source)

Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation

Da Eun Lee, Geunho Lim, Minoh Ko, Mari Kim et autres

Despite the immunomodulatory mechanism of immune checkpoint inhibitors (ICIs), systemic glucocorticoids are commonly used in advanced non-small cell lung cancer (NSCLC). Evidence regarding their effects on ICI outcomes is inconsistent, in part due to confounding by indication and immortal time bias. We …

kr, Éthiopie, Soudan (code pays fourni par la source)

Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial

Ming Gao, Young Joo Park, Chia-Chi Lin, Monika K Krzyzanowska et autres

cn, kr, tw, ca, my, br, ch, us (code pays fourni par la source)

LBA68 CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses

Geraldine Goss, Gail Elizabeth Darling, Virginie Westeel, K. Nakagawa et autres

ca, fr, jp, es, it, au, kr, cn, nl, pl (code pays fourni par la source)

LBA3: Sites of relapse and subsequent therapy in the BR.31 phase III study of durvalumab vs placebo in resected stage IB-IIIA NSCLC

V. Westeel, Glenwood D. Goss, Gail Elizabeth Darling, K. Nakagawa et autres

fr, ca, jp, es, it, au, kr, cn, nl, pl (code pays fourni par la source)

P3.03I.17 Exploring Autophagy Flux-Related Molecules to Overcome in Acquired Resistance to EGFR TKIs in NSCLC Patients Harboring EGFR Mutations

Jin Hyoung Kang, J.-O. Kim, M.-R. Lee, Mi‐Yeong Kim et autres

kr (code pays fourni par la source)

LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)

Geraldine Goss, Gail Elizabeth Darling, Virginie Westeel, K. Nakagawa et autres

ca, fr, jp, es, it, au, kr, cn, nl, pl, bd (code pays fourni par la source)

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, Yun Fan et autres

PURPOSE Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study …

tw, kr, cn, it, jp, mx, fr, es, us (code pays fourni par la source)

Are 19del and L858R really different disease entities?

Seoree Kim, Yunseok Heo, Young‐Ho Lee, Jin Hyoung Kang

Clinicians have recognized the similarities and differences between the two subtypes of common epidermal growth factor receptor (EGFR) mutations, but actual treatment strategies have not yet changed. The L858R mutation can be understood by considering the pharmacological conformational plasticity of the receptor …

ru, kr, ye, jp, cn, us (code pays fourni par la source)

Precision oncology clinical trials: A systematic review of phase II clinical trials with biomarker-driven, adaptive design.

Hee Yeon Lee, Hyerim Ha, Jin Hyoung Kang, Hye-Sung Park

e23005 Background: Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety. Methods: We systematically reviewed and analyzed the target studies. EMBASE …

kr (code pays fourni par la source)

Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design

Hyerim Ha, Hee Yeon Lee, Jee Hyun Kim, Do Yeun Kim et autres

Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety. We systematically reviewed and analyzed the target studies. EMBASE and PubMed searches …

kr (code pays fourni par la source)